Most Cost-Effective Setting (MCES) Program Drug List
Customize your policy alerts
Sign up for all AmeriHealth policy alerts
Know when AmeriHealth releases new policies or updates existing guidance.
Monitor payer policy activity
Defines the AmeriHealth Most Cost-Effective Setting Program listing medications for which the treatment setting must be approved as part of precertification; affects providers requesting medical-benefit administration of listed drugs for AmeriHealth members.
An Immunotherapy MCES Expansion listing oncology immunotherapy agents and criteria for outpatient continuation was launched May 1, 2026.
Multiple new drugs were added to the MCES Program with various 'Date Added' entries through 2026 (e.g., Avtozma, Bildyos, Bosaya, Enoby, Imaavy, Imuldosa, Qivigy, Starjemza).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.